Neuropathic pain

Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Giovedì, Maggio 2, 2024
Shift, FDA, Albuminuria, Investment, Research, Webcast, Chronic kidney disease, Endothelium, PROGRESS, American College of Cardiology, ASN, ID, AAK1, Overalls, Heart failure, Treatment, Conference, HCM, Neuropathic pain, Quality of life, Diabetes, Patient, SGLT2 inhibitor, Travel, Diabetic ketoacidosis, Obesity, CKD, Marketing, Research and development, American College, Vessel, Insulin, Diabetes management, Inhibitor, NDA, Coagulation, Administration, Society, Lexicon, Risk, Growth, Lexicon Pharmaceuticals, Pharmaceutical industry

Net sales for the quarter were $1.1 million reflecting 63 percent growth from the previous quarter.

Key Points: 
  • Net sales for the quarter were $1.1 million reflecting 63 percent growth from the previous quarter.
  • Lexicon is initiating a Phase 3 study of sotagliflozin in HCM, with an expected study start mid-year 2024.
  • Results from Two Large US Integrated Health System
    Revenues: Revenues for the first quarter of 2024 were $1.1 million, primarily from the commercialization of INPEFA.
  • Lexicon management will hold a live conference call and webcast today at 5:00 pm ET / 4:00 pm CT to review its financial and operating results and to provide a general business update.

Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

Retrieved on: 
Martedì, Aprile 23, 2024
Pain, FDA, Brain, Cancer, Food, Prognosis, Survival, Breast, Research, FABP5, Transport, Dicarboxylic acid, IND, Drug discovery, Patient, Metabolism, Neuropathic pain, FABP, FABP7, Chemotherapy-induced peripheral neuropathy, Pharmaceutical industry

Additionally, the evidence shows that both genetic and pharmacological inhibition of FABP7 led to reduced tumor cell growth, migration, and invasion in multiple studies.

Key Points: 
  • Additionally, the evidence shows that both genetic and pharmacological inhibition of FABP7 led to reduced tumor cell growth, migration, and invasion in multiple studies.
  • Moreover, inhibition of FABP7 improved host survival rates, particularly in brain cancers, indicating its role as a novel target in cancer.
  • In preclinical studies, ART26.12 demonstrated positive results in cancer, cancer bone pain, and painful neuropathies such as chemotherapy-induced peripheral neuropathy (CIPN).
  • For more information about Artelo Biosciences and our commitment to innovative therapies, please visit our website at www.artelobio.com

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Ad

Retrieved on: 
Martedì, Aprile 16, 2024
Insurance, Research, Patient, Change Healthcare, PALO, Neuropathic pain, Migraine, Lidocaine, Chronic pain, Growth, Nursing

This preliminary financial data has been prepared by and is the responsibility of Scilex.

Key Points: 
  • This preliminary financial data has been prepared by and is the responsibility of Scilex.
  • Scilex has not fully completed its review of these preliminary financial results for the quarter ended March 31, 2024.
  • Scilex’s actual results may differ materially from these preliminary financial results, and may be outside the estimated ranges.
  • For more information on Scilex Holding Company, refer to www.scilexholding.com
    For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com .

Encoded Therapeutics Provides Pipeline Updates From Its Vector Engineering Platform Ahead of Four Preclinical Presentations at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Retrieved on: 
Martedì, Aprile 23, 2024
Biotechnology, Genetics, Health, Factorization of polynomials, Lennox–Gastaut syndrome, Brain, DRG, DSM-IV codes, SCN9A, Dorsal root ganglion, Dravet syndrome, ETF, Central nervous system disease, Gene silencing, LGS, Transgene, Neuroscience, Abstract, Code, CNS, GABAergic, Engineering, Res, Interneuron, MAPT, Angelman syndrome, Neuropathic pain, Central nervous system, Therapy, MicroRNA, Vaccine

Presentations will highlight progress of preclinical programs for Angelman syndrome, Lennox-Gastaut syndrome (LGS), STXBP1-related disorders (STXBP1-RD), Alzheimer’s disease (MAPT) and neuropathic pain (SCN9A), together with innovations in the company’s vector engineering platform.

Key Points: 
  • Presentations will highlight progress of preclinical programs for Angelman syndrome, Lennox-Gastaut syndrome (LGS), STXBP1-related disorders (STXBP1-RD), Alzheimer’s disease (MAPT) and neuropathic pain (SCN9A), together with innovations in the company’s vector engineering platform.
  • “Our ASGCT presentations showcase the depth and versatility of our vector engineering platform to develop highly specific precision therapies for CNS disorders with high unmet need,” said Stephanie Tagliatela, Chief Scientific Officer at Encoded.
  • “Combining our novel regulatory elements and transgenes provides control of expression in target cells, potentially enabling treatment of devastating, intractable diseases.
  • Engineered transgenes include transcription factors (eTFs) that upregulate the expression of endogenous genes as well miRNA sequences derived from Encoded’s miRNA discovery platform.

Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain

Retrieved on: 
Giovedì, Aprile 18, 2024
Health, FDA, Neurology, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, VRTX, Pain, Pregabalin, Safety, NDA, Food, New Drug Application, DPN, Sciatica, Fast track (FDA), Week, Patient, Medicine, Neuropathic pain, LSR, Vertex, Vertex Pharmaceuticals, Pharmaceutical industry

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades.
  • Following the positive Phase 3 results in acute pain announced in January 2024, the Food and Drug Administration (FDA) has granted a rolling New Drug Application (NDA) submission for suzetrigine in moderate-to-severe acute pain.
  • Suzetrigine was previously granted FDA Fast Track and Breakthrough Therapy designations in moderate-to-severe acute pain.
  • The company intends to advance its next generation NaV1.8 pain signal inhibitor VX-993 oral formulation into Phase 2 acute pain and peripheral neuropathic pain studies later this year.

EQS-News: Grünenthal reports strong 2023 results with record revenue and continued investments in R&D and acquisitions

Retrieved on: 
Mercoledì, Aprile 10, 2024
Trigeminal neuralgia, Knee, Growth, Rheumatoid arthritis, Neuropathic pain, Pain, GRM, DPN, ESG, Patient, Prednisolone, Research, Sustainalytics, Breakthrough, Glucocorticoid, Quality of life, PSNP, Research and development, Investment, Diabetic neuropathy, NOP, Kyowa Kirin, Osteoarthritis, RTX, Food, FDA, Corporation, Pharmaceutical industry

In 2023, Grünenthal generated €1.8 billion in revenues, an increase of 10 percent over the prior year.

Key Points: 
  • In 2023, Grünenthal generated €1.8 billion in revenues, an increase of 10 percent over the prior year.
  • Grünenthal owns 51 percent of the new enterprise Grünenthal Meds and intends to acquire the remaining share in 2026.
  • Aachen, Germany, 25 March 2024 – Grünenthal, the leading pharmaceutical company in pain research and management, released its 2023 full-year results, announcing a double-digit revenue growth.
  • The 2023 results were driven by strong business performance in the United States, Latin America and Europe.

Chromocell Issues Letter to Stockholders from Chief Executive Officer

Retrieved on: 
Martedì, Aprile 9, 2024
Erythromelalgia, Consultant, Toxicity, ChromeOS, Abrasion (medical), Letter, Uveitis, Growth, Opioid, Neuropathic pain, Incidence, Physiology, Patient, NAV, Mortality, IPO, Human, Rash, Outline, Lawyer, Annual report, CHRO, PRK, Pain, Glaucoma, NSAID, Therapy, Family, Photorefractive keratectomy, FDA, Liver, Food, Pharmaceutical industry

We transferred $2.2 million in liabilities to Chromocell Corporation in exchange for 2,600 shares of Series C Convertible Redeemable Preferred Stock (“Series C Preferred Stock”).

Key Points: 
  • We transferred $2.2 million in liabilities to Chromocell Corporation in exchange for 2,600 shares of Series C Convertible Redeemable Preferred Stock (“Series C Preferred Stock”).
  • Our CEO has agreed to further defer a considerable portion of his accrued compensation, affirming the belief in Chromocell’s mission.
  • We truly feel that our IPO and recent therapeutic development activities have positioned Chromocell for long term growth and success.
  • I wish to thank you for your support and remain a resource to each of you as we move forward.

Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update

Retrieved on: 
Lunedì, Aprile 1, 2024
Blood pressure, EEG, Epilepsy, Bradycardia, Trevena, Rat, Neuropathic pain, Seizure, Central nervous system, Patient, CNS, TMS, Hospital, Sale, Chronic pain, NIH, IND, POC, Safety, Astrocyte, Status epilepticus, Neuroinflammation, Pharmaceutical industry

CHESTERBROOK, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the fourth quarter ended December 31, 2023 and provided an overview of its recent operational highlights.

Key Points: 
  • Given performance to date, we are reducing commercial support and reviewing alternatives for OLINVYK to preserve capital,” said Carrie Bourdow, President and CEO of Trevena.
  • OLINVYK will remain available for purchase by customers, who can continue to order the product through their normal channels.
  • In a review of safety and tolerability across both studies, TRV045 was well tolerated with results generally consistent with prior first-in-human studies.
  • For the fourth quarter of 2023, the Company reported a net loss attributable to common stockholders of $16.5 million, or $1.06 per share, compared to $7.0 million, or $0.73 per share in the fourth quarter of 2022.

Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update

Retrieved on: 
Lunedì, Marzo 25, 2024
ART, Research, Depression, Neuropathic pain, Argyreia nervosa, Weight gain, Cachexia, Anxiety, Cancer, IND, Investment, Safety, Pain, FDA, Cannabidiol, Pharmaceutical industry

SOLANA BEACH, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today reported financial and operating results for the fiscal year ended December 31, 2023 and provided a business update.

Key Points: 
  • SOLANA BEACH, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today reported financial and operating results for the fiscal year ended December 31, 2023 and provided a business update.
  • “We made substantial progress on multiple programs last year,” commented Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences.
  • Cash and Investments: Cash and investments totalled $10.4 million as of December 31, 2023.
  • R&D Expenses: Research and development expenses were $5.7 million for the year ended December 31, 2023, compared to $4.3 million for the same period in 2022.

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Mercoledì, Marzo 27, 2024
Science, Other Science, Research, Pharmaceutical, Optical, Surgery, General Health, Health, Momentum, YAG, Toric, Failure, IOP, Retinal, Glaucoma, Exercise, DSM-IV codes, Neuropathic pain, ASCRS, History, Sale, Contact, Dry, Refraction, Bausch & Lomb, Eye, System, Keratoconus, Medication discontinuation, Pain, Corneal topography, Telecanthus, Astigmatism, Aphakia, Correction, Uveitis, Surgeon, Diabetes, Risk, Eye injury, CTK, Retinal detachment, Side, Trial of the century, Visual acuity, Diagnosis, Safety, Contraindication, Emmetropia, Vision, Taste, Dry eye syndrome, Intraocular lens, Presbyopia, Real, Floater, Magnetic resonance, Contrast (vision), Human, GLARE, Infection, Use, FDA, Ranibizumab, Muscular dystrophy, Sickle cell disease, Refractive surgery, Retina, Direction, IDE, Allergy, User, Society, Bleeding, Autoimmune disease

In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.

Key Points: 
  • In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.
  • Bausch + Lomb activities at ASCRS:
    “Assessment of the Spectacle Independence and Visual Outcomes Following Bilateral Implantation of a Novel Toric IOL* Among Cataract Patients.” Harasymowycz et al.
  • “Outcomes of an Ultra-Low Cylinder Powered (0.90 D) Toric versus Non-Toric IOL in Low Astigmatic Patients Undergoing Cataract Surgery.” Muzychuk et al.
  • “Quality of Vision and Clinical Outcomes of a Novel Trifocal IOL* Implanted Bilaterally After Cataract Surgery: A Canadian Multicenter Study.” Harasymowycz et al.